This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX Laboratories (IDXX) Earnings, Revenues Rise in Q1
by Zacks Equity Research
IDEXX (IDXX) rides on strength in CAG business in Q1. A raised EPS guidance buoys optimism.
QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.
Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.
Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.
Allscripts (MDRX) Q1 Earnings & Revenues Lag, Bookings Rise
by Zacks Equity Research
Allscripts (MDRX) witnesses strong segmental performances; a solid guidance encourages.
DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues drive DexCom's (DXCM) Q1 results.
Cardinal Health (CAH) Misses on Q3 Earnings, Lowers '18 View
by Zacks Equity Research
Cardinal Health (CAH) saw a tepid Q3 owing to declining profits at the Pharmaceutical unit despite a decent performance by the Medical segment.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low
by Zacks Equity Research
Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.
Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.
Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.
Pacific Biosciences (PACB) Loss Wider Than Expected in Q1
by Zacks Equity Research
Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.
Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.
Cerner (CERN) Meets Q1 Earnings Estimates, Lowers '18 View
by Zacks Equity Research
Lower revenues stemming from lesser-than-expected subscription bookings hurt Cerner's (CERN) Q1 results.
Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.
CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow
by Zacks Equity Research
CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.
AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.
NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.
Ecolab (ECL) Q1 Earnings & Revenues Top, '18 Guidance Solid
by Zacks Equity Research
Solid performance in Global Industrial and Global Institutional segments gave a boost to Ecolab's (ECL) earnings and revenues in Q1.
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
PerkinElmer (PKI) Q1 Earnings & Revenues Top, '18 View Up
by Zacks Equity Research
Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.
Hill-Rom (HRC) Earnings & Revenues Beat in Q2, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q2.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.
ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.